Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.52 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968593 | 0.86 | MAPT (0.68) | MEN1KMT2AMAPTPLIN1LMNA | |
| SCHEMBL4963613 | 0.83 | KMT2A (0.50) | MEN1KMT2AMAPTPLIN1LMNA | |
| SCHEMBL4966712 | 0.83 | KMT2A (0.50) | MEN1KMT2AMAPTPLIN1LMNA | |
| SCHEMBL31483412 | 0.81 | MAPT (0.54) | MEN1KMT2AMAPTPLIN1LMNA | |
| SCHEMBL31483471 | 0.81 | MAPT (0.57) | MEN1KMT2AMAPTPLIN1LMNA | |
| SCHEMBL22877265 | 0.80 | HPGD (0.52) | MEN1KMT2AMAPTPLIN1LMNA | |
| SCHEMBL14117364 | 0.80 | LMNA (0.72) | MEN1KMT2AMAPTPLIN1LMNA | |
| SCHEMBL22877267 | 0.77 | POLB (0.56) | MEN1KMT2AMAPTPLIN1LMNA | |
| SCHEMBL22877240 | 0.77 | NPC1 (0.63) | MEN1KMT2AMAPTPLIN1LMNA | |
| SCHEMBL22877274 | 0.75 | KMT2A (0.47) | MEN1KMT2AMAPTPLIN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171802-A1 | Methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function and photostabilizing methods | L'OREAL (FR) | 2008-07-17 | — | — | US | disclosed |
| US-7354571-B2 | Photoprotective compositions comprising methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function | L'OREAL (FR) | 2008-04-08 | — | — | US | disclosed |
| EP-1594880-B1 | PHOTOPROTECTIVE COMPOSITIONS BASED ON METHYLTRIALKYLSILANES CONTAINING A CINNAMATE, CINNAMAMIDE, BENZALMALONAMIDE OR BENZALMALONATE FUNCTION | OREAL (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20060018848-A1 | Photoprotective compositions comprising methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function | L'OREAL (FR) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171802-A1 | Methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function and photostabilizing methods | KCNN1, KCNN2, CMBL | MEN1 393/4885KMT2A 653/4885MAPT 3422/4885 |
| US-20060018848-A1 | Photoprotective compositions comprising methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function | TRPM7, TRPM6, KCNN1 | MEN1 606/4885KMT2A 1192/4885MAPT 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.